Article

Bbarrons.com on 2021-05-28 22:05

This Just-Approved Amgen Drug Is the First to Hit a Hard Target in Cancer

Amgen's newest cancer drug is the first KRAS inhibitor class to gain approval, after decades of trying by other drug developers. Mirati hopes to ...

Related news

BAmgen Acquires a Cancer Drug. Expect More Deals.barrons.com
Bristol , Phase 2 , Asia
MAmgen stock climbs as Wall Street cheers potential new blockbuster cancer drug marketwatch.com
Wall Street
FDA approves Amgen drug for small cell lung cancer staradvertiser.com
Wall Street , Thousand Oaks
BAmgen Falls as Cancer-Drug Report Fails to Impress Investors barrons.com
Phase 1 , Stock Island
PFDA OKs Amgen skin cancer drug Imlygic pacbiztimes.com
PEuropean regulators approve Amgen cancer drug Kyprolis pacbiztimes.com
FDA weighs target population for Amgen cholesterol drug TimesDaily.com
Amgen Wins Approval for Pathbreaking Lung Cancer Drug wsj.com
Thousand Oaks
PAmgen cancer drug Kyprolis to get expedited review from FDA pacbiztimes.com
PAmgen submits data on cancer drug Kyprolis to FDA pacbiztimes.com
PAmgen partners with Biocartis on diagnostic tests for cancer drug pacbiztimes.com
Amgen says study finds its cancer drug tops rival’s seattletimes.com
Drug duo approved for aggressive thyroid cancer wbrc.com
Switzerland , United States
MSanofi, Regeneron have skin-cancer drug approved marketwatch.com
PAmgen seeks license for biosimilar version of oncology drug Rituxan pacbiztimes.com
Europe , Ireland , Thousand Oaks
BMerck, Roche, Amgen Stocks React to Release of Cancer-Drug Data barrons.com
Phase 2 , Phase 1